Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

NCT07109336 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

790

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DEVICE: Heterogeneous Treatment Effect-Based Decision Model

Sponsor

Zhongda Hospital